Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.2991
Abstract: RANKL is a key regulator of bone resorption that may also modulate glucose metabolism. Denosumab (DMAb) is a fully human monoclonal antibody that binds RANKL and was associated with fracture risk reduction in the FREEDOM… read more here.
Keywords: trial; diabetes prediabetes; freedom trial; effect denosumab ... See more keywords